Cargando…
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
BACKGROUND: Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and increase weight loss efficacy in combination with...
Autores principales: | Sonne, Nina, Karsdal, Morten A., Henriksen, Kim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085567/ https://www.ncbi.nlm.nih.gov/pubmed/33166741 http://dx.doi.org/10.1016/j.molmet.2020.101109 |
Ejemplares similares
-
The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist Therapy
por: Sonne, Nina, et al.
Publicado: (2022) -
The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
por: Larsen, Anna Thorsø, et al.
Publicado: (2021) -
Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat model
por: Katri, Anna, et al.
Publicado: (2021) -
KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats
por: Andreassen, K.V., et al.
Publicado: (2021) -
Combining naproxen and a dual amylin and calcitonin receptor agonist improves pain and structural outcomes in the collagen-induced arthritis rat model
por: Katri, Anna, et al.
Publicado: (2019)